Clinical Trial Update: Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating olaparib in combination with radiation therapy for triple-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: Institut Curie | Conditions: Breast Neoplasms, Triple-Negative, Breast Neoplasm Malignant Female | Phase 1 | Status: COMPLETED